MediWound Ltd. Stock News

MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid ®

MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares

MediWound Expands Global Reach with Marketing Approval of NexoBrid ® in Australia

MediWound's NexoBrid ® to be Highlighted in 36 Scientific Presentations at the 21st European Burns Association Congress YAVNE, Israel, September 2, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced its participation at the 21st European Burns Association (EBA) Congress, taking place September 3-6, 2025, in Berlin,...

MediWound is a niche biotech with strong R&D, FDA-approved products, and a promising pipeline, but remains underfollowed and volatile. Despite weak current performance and negative metrics, the company has a solid cash runway, no debt, and recent strategic investments. NexoBrid's expanded approvals and rising hospital orders, plus a new facility, position MediWound for significant revenue growt...

YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27th Ann...

MediWound Ltd. (NASDAQ:MDWD ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Barry J.

VALUE Phase III Trial of EscharEx ® in Venous Leg Ulcers Continues to Enroll Patients NexoBrid ® Manufacturing Expansion on Track; Full Operational Capacity Expected by Year-End 2025 Additional Strategic Research Collaborations Established with Essity and Convatec Second Quarter 2025 Revenue of $5.7 Million, Up 43% from Prior Quarter Conference Call Today, August 14, 2025, at 8:30am Eastern Tim...